Circulation and degradation of GIP and GLP-1

被引:221
|
作者
Deacon, CF [1 ]
机构
[1] Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
关键词
glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; gut hormone; incretin; dipeptidyl peptidase IV; neutral endopeptidase 24.11;
D O I
10.1055/s-2004-826160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 50 条
  • [21] Effects of an RYGB on β-Cell Sensitivity to GLP-1 and GIP examined
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (12):
  • [22] How May GIP Enhance the Therapeutic Efficacy of GLP-1?
    Samms, Ricardo J.
    Goghlan, Matthew P.
    Sloop, Kyle W.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2020, 31 (06): : 410 - 421
  • [23] Central administration of GLP-1 and GIP decreases feeding in mice
    NamKoong, Cherl
    Kim, Min Sun
    Jang, Byeong-Tak
    Lee, Young Hee
    Cho, Young-Mm
    Choi, Hyung Jin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 490 (02) : 247 - 252
  • [24] THE INSULINOTROPIC EFFECT OF GIP AND GLP-1 IN HEALTHY AND DIABETIC SUBJECTS
    MCALOONDYKE, M
    FUKAGAWA, NK
    HABENER, J
    ANDERSEN, DK
    ELAHI, D
    REGULATORY PEPTIDES, 1992, 40 (02) : 205 - 205
  • [25] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [26] GIP and GLP-1, the two incretin hormones: Similarities and differences
    Seino, Yutaka
    Fukushima, Mitsuo
    Yabe, Daisuke
    JOURNAL OF DIABETES INVESTIGATION, 2010, 1 (1-2): : 8 - 23
  • [27] Incretin effect: GLP-1, GIP, DPP4
    Kazakos, Kyriakos
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 : S32 - S36
  • [28] Effect of GIP and GLP-1 antagonists on insulin release in the rat
    Tseng, CC
    Zhang, XY
    Wolfe, MM
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 276 (06): : E1049 - E1054
  • [29] CART is a regulator of GIP and GLP-1 expression and secretion in vitro
    Shcherbina, L.
    Wierup, N.
    DIABETOLOGIA, 2014, 57 : S218 - S218
  • [30] The incretin system in healthy humans: The role of GIP and GLP-1
    Hoist, Jens Juul
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 96 : 46 - 55